help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 70, No. 4 920-924
doi:10.1210/jcem-70-4-920
Copyright © 1990 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RIIS, B. J.
Right arrow Articles by JACOBSON, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RIIS, B. J.
Right arrow Articles by JACOBSON, J.

Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists?

B. J. RIIS, C. CHRISTIANSEN, J. S. JOHANSEN and J. JACOBSON

Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen Glostrup, Denmark
the Department of Obstetrics and Gynecology, Södertälje Hospital (J.J.) Södertälje, Sweden

Address all correspondence and requests for reprints to: Bente Juel Riis, Department of Clinical Chemistry, Glostrup Hospital, DKH 2600 Glostrup, Denmark.

Recent studies have shown that treatment with the LHRH agonist nafarelin gives symptomatic and objective relief to women with endometriosis. Such a treatment, however, results in increased bone turnover and loss of bone mass. In the present study 17 women with endometriosis were treated with 400 mg nafarelin combined with 1.2 mg norethisterone (NET) for 6 months, followed by 6 months with only 1.2 mg NET. The data were compared to data from a previously published study of 9 women treated for 6 months with 400 mg nafarelin alone, followed by 6 months without treatment.

In the group treated with nafarelin plus NET the biochemical parameter of bone resorption (fasting urinary hydroxyproline) remained virtually unchanged, compared to a highly significant increase in the nafarelin-treated group. Estimates of bone formation (serum alkaline phosphatase and plasma bone Gla protein) increased in the nafarelin plus NET group, but to only a minor extent compared to those in the nafarelin group. In addition, bone mineral in the forearm, the spine, and the total skeleton remained virtually unchanged in the group treated with nafarelin plus NET, compared to the bone loss of 2-6%/6 months in the nafarelin group. We conclude that addition of NET to nafarelin treatment of endometriosis seems to have a bone-sparing effect.

Received June 20, 1989.




This article has been cited by other articles:


Home page
J EndocrinolHome page
A. E Lemus, J. Enriquez, A. Hernandez, R. Santillan, and G. Perez-Palacios
Bioconversion of norethisterone, a progesterone receptor agonist into estrogen receptor agonists in osteoblastic cells
J. Endocrinol., February 1, 2009; 200(2): 199 - 206.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
J. Enriquez, A. E. Lemus, J. Chimal-Monroy, H. Arzate, G. A Garcia, B. Herrero, F. Larrea, and G. Perez-Palacios
The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites
J. Endocrinol., June 1, 2007; 193(3): 493 - 504.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
H. Fernandez, C. Lucas, B. Hedon, J.L. Meyer, J.M. Mayenga, and C. Roux
One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial
Hum. Reprod., June 1, 2004; 19(6): 1465 - 1471.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. H. Tobias, S. Clarke, K. Mitchell, S. Robins, H. Amer, and W. D. Fraser
Analysis of the Contribution of Dydrogesterone to Bone Turnover Changes in Postmenopausal Women Commencing Hormone Replacement Therapy
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1194 - 1198.
[Abstract] [Full Text]


Home page
Physiol. Rev.Home page
J. E. Compston
Sex Steroids and Bone
Physiol Rev, January 1, 2001; 81(1): 419 - 447.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. K. Miller and A. Klibanski
Amenorrheic Bone Loss
J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1775 - 1783.
[Full Text]


Home page
JAMAHome page
J. S. Finkelstein, A. Klibanski, A. L. Arnold, T. L. Toth, M. D. Hornstein, and R. M. Neer
Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34): A Randomized Controlled Trial
JAMA, September 23, 1998; 280(12): 1067 - 1073.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. A. Amama, M. Taga, and H. Minaguchi
The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 333 - 338.
[Abstract] [Full Text]


Home page
NEJMHome page
J. S. Finkelstein, A. Klibanski, E. H. Schaefer, M. D. Hornstein, I. Schiff, and R. M. Neer
Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency
N. Engl. J. Med., December 15, 1994; 331(24): 1618 - 1623.
[Abstract] [Full Text]


Home page
Arch Intern MedHome page
G. E.-H. Fuleihan, E. M. Brown, K. Curtis, M. J. Berger, B. M. Berger, R. Gleason, and M. S. LeBoff
Effect of Sequential and Daily Continuous Hormone Replacement Therapy on Indexes of Mineral Metabolism
Arch Intern Med, September 1, 1992; 152(9): 1904 - 1909.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society